SCHEMBL212326

SCHEMBL212326

O=C1C=CC(=O)N1C1CCCCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 3/20 0.52
CYP3A4 P08684 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
CREBBP Q92793 1/20 0.40
HSD17B10 Q99714 1/20 0.40
OPRM1 P35372 2/20 0.39
OPRK1 P41145 2/20 0.39
OPRL1 P41146 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28719 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL209153 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL15492440 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL25118469 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL1059882 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL25434872 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL20375020 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL24079397 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL13452762 0.98 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4
SCHEMBL28961005 0.98 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932432-B2 Polymers of maleimide and cycloolefinic monomers as permanent dielectric materials PROMERUS, LLC (US) 2018-04-03 US claimed
WO-2016179452-A1 POLYMERS OF MALEIMIDE AND CYCLOOLEFINIC MONOMERS AS PERMANENT DIELECTRIC MATERIALS PROMERUS, LLC (US) 2016-11-10 WO claimed
US-20160326292-A1 POLYMERS OF MALEIMIDE AND CYCLOOLEFINIC MONOMERS AS PERMANENT DIELECTRIC MATERIALS SUMITOMO BAKELITE CO., LTD. (JP) 2016-11-10 US claimed
EP-1817376-B1 HYBRID THERMOSETTING COMPOSITION 3M INNOVATIVE PROPERTIES CO (US) 2012-08-22 EP claimed
EP-1817353-A1 BRANCHED POLYMER 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-08-15 EP claimed
EP-1817376-A1 HYBRID THERMOSETTING COMPOSITION 3M Innovative Properties Company (US) 2007-08-15 EP claimed
WO-2006060092-A1 HYBRID THERMOSETTING COMPOSITION 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-06-08 WO claimed
WO-2006060086-A1 BRANCHED POLYMER 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-06-08 WO claimed
US-20060116492-A1 Branched polymer 3M INNOVATIVE PROPERTIES COMPANY 2006-06-01 US claimed
US-20060116476-A1 Hybrid thermosetting composition 3M INNOVATIVE PROPERTIES COMPANY 2006-06-01 US claimed
US-12476201-B2 Method for manufacturing electronic component, resin composition for temporary protection, and resin film for temporary protection SHOWA DENKO MATERIALS CO LTD (JP) 2025-11-18 US disclosed
CN-120044752-A Photosensitive resin composition 东京应化工业株式会社 2025-05-27 CN disclosed
CN-120044751-A Photosensitive resin composition 东京应化工业株式会社 2025-05-27 CN disclosed
CN-112930584-B Method for manufacturing semiconductor device and adhesive film for processing semiconductor wafer 株式会社力森诺科 2024-11-15 CN disclosed
CN-110317174-B Hydrogen barrier agent, composition for forming hydrogen barrier film, method for producing hydrogen barrier film, and electronic device 东京应化工业株式会社 2024-10-22 CN disclosed
US-20040235849-A1 Tetrahydroquinoxalines acting as bradykinin antagonists BAYER HEALTHCARE AG (DE) 2004-11-25 US disclosed
EP-1411948-A1 TETRAHYDROQUINOXALINES ACTING AS BRADYKININ ANTAGONISTS Bayer Aktiengesellschaft (DE) 2004-04-28 EP disclosed
US-20040032547-A1 Optical film and display system NITTO DENKO CORPORATION (JP) 2004-02-19 US disclosed
WO-2003007958-A1 TETRAHYDROQUINOXALINES ACTING AS BRADYKININ ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed
EP-1160591-A1 TRANSPARENT FILM Kaneka Corporation (JP) 2001-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235849-A1 Tetrahydroquinoxalines acting as bradykinin antagonists BDKRB2, BDKRB1, LTB4R2 ALDH1A1 4292/4885SMN1; SMN2 3726/4885CYP2C9 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.